NasdaqCM:CTSO

Stock Analysis Report

Executive Summary

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide.


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Cytosorbents's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTSO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.5%

CTSO

-7.5%

US Medical Equipment

-7.6%

US Market


1 Year Return

-30.2%

CTSO

10.7%

US Medical Equipment

10.2%

US Market

Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned 10.7% over the past year.

Return vs Market: CTSO underperformed the US Market which returned 10.2% over the past year.


Shareholder returns

CTSOIndustryMarket
7 Day-9.5%-7.5%-7.6%
30 Day19.7%-6.6%-4.5%
90 Day41.4%-2.3%-0.6%
1 Year-30.2%-30.2%11.6%10.7%12.5%10.2%
3 Year0.7%0.7%64.4%59.8%37.1%28.3%
5 Year-47.8%-47.8%98.6%77.8%60.8%43.2%

Price Volatility Vs. Market

How volatile is Cytosorbents's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cytosorbents undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CTSO ($5.64) is trading below our estimate of fair value ($53.87)

Significantly Below Fair Value: CTSO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CTSO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CTSO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTSO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTSO is overvalued based on its PB Ratio (27.2x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Cytosorbents forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTSO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTSO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTSO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTSO's revenue (30.3% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: CTSO's revenue (30.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cytosorbents performed over the past 5 years?

-4.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTSO is currently unprofitable.

Growing Profit Margin: CTSO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of -4.6% per year.

Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.4%).


Return on Equity

High ROE: CTSO has a negative Return on Equity (-307.69%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cytosorbents's financial position?


Financial Position Analysis

Short Term Liabilities: CTSO's short term assets ($22.4M) exceed its short term liabilities ($9.3M).

Long Term Liabilities: CTSO's short term assets ($22.4M) exceed its long term liabilities ($12.6M).


Debt to Equity History and Analysis

Debt Level: CTSO's debt to equity ratio (223%) is considered high.

Reducing Debt: Insufficient data to determine if CTSO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: CTSO has a low level of unsold assets or inventory.

Debt Coverage by Assets: CTSO's debt is covered by short term assets (assets are 1.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTSO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cytosorbents's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.0%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Phillip Chan (49yo)

11.1yrs

Tenure

US$1,247,295

Compensation

Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of Cytosorbents Corporation since January 2009 and serves as its President. Dr. Chan serves as a Partner of NJTC Venture Fund. He co-fo ...


CEO Compensation Analysis

Compensation vs Market: Phillip's total compensation ($USD1.25M) is about average for companies of similar size in the US market ($USD1.14M).

Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Phillip Chan
CEO, President & Director11.1yrsUS$1.25m1.18% $2.2m
Kathleen Bloch
CFO & Secretary6.8yrsUS$953.58k0.27% $498.8k
Vincent Capponi
Chief Operating Officer14.6yrsUS$1.08m0.35% $641.2k
Christian Steiner
Vice President of Sales & Marketing7.7yrsno datano data
Christopher Cramer
Vice President of Business Development6.8yrsno datano data
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant2.7yrsUS$97.32kno data

7.3yrs

Average Tenure

62.5yo

Average Age

Experienced Management: CTSO's management team is seasoned and experienced (7.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Phillip Chan
CEO, President & Director11.1yrsUS$1.25m1.18% $2.2m
Robert Bartlett
Co-Chairman of Cardiac Surgery Advisory Board & Consultant2.7yrsUS$97.32kno data
Al Kraus
Chairman of the Board11.1yrsUS$184.83k0.17% $314.4k
Alan Sobel
Independent Director5.3yrsUS$100.18kno data
Edward Jones
Independent Director12.8yrsUS$91.38k0.017% $31.0k
John Kellum
Member of Critical Care Advisory Board0yrsno datano data
Ronald Maier
Chairman of the Trauma Advisory Board0yrsno datano data
Mitchell Cohen
Member of Trauma Advisory Board0yrsno datano data
Raul Coimbra
Member of Trauma Advisory Board0yrsno datano data
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board5.4yrsno datano data

8.3yrs

Average Tenure

71yo

Average Age

Experienced Board: CTSO's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CTSO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.


Top Shareholders

Company Information

Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytosorbents Corporation
  • Ticker: CTSO
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$182.870m
  • Shares outstanding: 32.42m
  • Website: https://www.cytosorbents.com

Number of Employees


Location

  • Cytosorbents Corporation
  • 7 Deer Park Drive
  • Suite K
  • Monmouth Junction
  • New Jersey
  • 8852
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTSONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2006
HQE1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2006

Biography

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 01:14
End of Day Share Price2020/02/26 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.